Patents by Inventor Guido Hartmann

Guido Hartmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODY THAT BINDS TO VEGF AND IL-1BETA AND METHODS OF USE
    Publication number: 20240101657
    Abstract: The present invention relates to anti-VEGF/anti-IL-1beta antibodies and methods of using the same.
    Type: Application
    Filed: November 15, 2023
    Publication date: March 28, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: ROLAND BECKMANN, JOERG BENZ, STEFAN DENGL, CHRISTIAN GASSNER, GUIDO HARTMANN, PETER MICHAEL HUELSMANN, SABINE IMHOF-JUNG, KRISTIAN HOBOLT JENSEN, HUBERT KETTENBERGER, STEFAN LORENZ, JOERG MOELLEKEN, OLAF MUNDIGL
  • Antibody that binds to VEGF and IL-1beta and methods of use
    Patent number: 11866490
    Abstract: The present invention relates to anti-VEGF/anti-IL-1beta antibodies and methods of using the same.
    Type: Grant
    Filed: September 8, 2021
    Date of Patent: January 9, 2024
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Roland Beckmann, Joerg Benz, Stefan Dengl, Christian Gassner, Guido Hartmann, Peter Michael Huelsmann, Sabine Imhof-Jung, Kristian Hobolt Jensen, Hubert Kettenberger, Stefan Lorenz, Joerg Moelleken, Olaf Mundigl
  • ANTIBODY THAT BINDS TO VEGF-A AND ANG2 AND METHODS OF USE
    Publication number: 20230374119
    Abstract: The present invention relates to anti-VEGF-A/anti-ANG2 antibodies, e.g. in the form of a bispecific Fab fragment, and methods of using the same.
    Type: Application
    Filed: June 22, 2023
    Publication date: November 23, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Roland Beckmann, Sebastian Fenn, Guido Hartmann, Sabine lmhof-Jung, Kristian Hobolt-Jensen, Joerg Moelleken, Michael Molhoj, Christian Schantz, Janina Speck, Christoph UlImer, Barbara Weiser
  • Antibody that binds to VEGF-A and ANG2 and methods of use
    Patent number: 11732036
    Abstract: The present invention relates to anti-VEGF-A/anti-ANG2 antibodies, e.g. in the form of a bispecific Fab fragment, and methods of using the same.
    Type: Grant
    Filed: September 3, 2021
    Date of Patent: August 22, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Roland Beckmann, Sebastian Fenn, Guido Hartmann, Sabine Imhof-Jung, Kristian Hobolt-Jensen, Joerg Moelleken, Michael Molhoj, Christian Schantz, Janina Speck, Christoph Ullmer, Barbara Weiser
  • ANTIBODY THAT BINDS TO VEGF-A AND ANG2 AND METHODS OF USE
    Publication number: 20220073599
    Abstract: The present invention relates to anti-VEGF-A/anti-ANG2 antibodies, e.g. in the form of a bispecific Fab fragment, and methods of using the same.
    Type: Application
    Filed: September 3, 2021
    Publication date: March 10, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Roland Beckmann, Sebastian Fenn, Guido Hartmann, Sabine Imhof-Jung, Kristian Hobolt-Jensen, Joerg Moelleken, Michael Molhoj, Christian Schantz, Janina Speck, Christoph Ullmer, Barbara Weiser
  • ANTIBODY THAT BINDS TO VEGF AND IL-1BETA AND METHODS OF USE
    Publication number: 20220041707
    Abstract: The present invention relates to anti-VEGF/anti-IL-1beta antibodies and methods of using the same.
    Type: Application
    Filed: September 8, 2021
    Publication date: February 10, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: ROLAND BECKMANN, JOERG BENZ, STEFAN DENGL, CHRISTIAN GASSNER, GUIDO HARTMANN, PETER MICHAEL HUELSMANN, SABINE IMHOF-JUNG, KRISTIAN HOBOLT JENSEN, HUBERT KETTENBERGER, STEFAN LORENZ, JOERG MOELLEKEN, OLAF MUNDIGL
  • HUMAN FCRN-BINDING MODIFIED ANTIBODIES AND METHODS OF USE
    Publication number: 20210395355
    Abstract: Herein is reported the use of an antibody comprising an Fc-region with abolished FcRn binding for the transport of a soluble receptor ligand from the eye over the blood-ocular-barrier into the blood circulation.
    Type: Application
    Filed: July 12, 2021
    Publication date: December 23, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Guido Hartmann, Joerg Regula, Matthias Rueth, Wolfgang Schaefer, Tilman Schlothauer
  • Antibody that binds to VEGF and IL-1beta and methods of use
    Patent number: 11130804
    Abstract: The present invention relates to anti-VEGF/anti-IL-1beta antibodies and methods of using the same.
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: September 28, 2021
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Roland Beckmann, Joerg Benz, Stefan Dengl, Christian Gassner, Guido Hartmann, Peter Michael Huelsmann, Sabine Imhof-Jung, Kristian Hobolt Jensen, Hubert Kettenberger, Stefan Lorenz, Joerg Moelleken, Olaf Mundigl
  • Human FcRn-binding modified antibodies and methods of use
    Patent number: 11091541
    Abstract: Herein is reported the use of an antibody comprising an Fc-region with abolished FcRn binding for the transport of a soluble receptor ligand from the eye over the blood-ocular-barrier into the blood circulation.
    Type: Grant
    Filed: October 29, 2015
    Date of Patent: August 17, 2021
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Guido Hartmann, Joerg Thomas Regula, Matthias Rueth, Wolfgang Schaefer, Tilman Schlothauer
  • Bispecific antibodies and methods of use in ophthalmology
    Patent number: 10730938
    Abstract: Herein are reported novel bispecific antibodies that specifically bind to two different antigens selected from the group consisting of human ANG2, human VEGF, human IL-1beta and human PDGF-B.
    Type: Grant
    Filed: May 9, 2017
    Date of Patent: August 4, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Marc Bedoucha, Sebastian Breuer, Stefan Dengl, Christian Gassner, Guy Georges, Sabine Gruener, Guido Hartmann, Peter Michael Huelsmann, Hubert Kettenberger, Joerg Moelleken, Michael Molhoj, Olaf Mundigl, Joerg Thomas Regula, Ralf Schumacher, Barbara Weiser
  • ANTIBODY THAT BINDS TO VEGF AND IL-1BETA AND METHODS OF USE
    Publication number: 20200199214
    Abstract: The present invention relates to anti-VEGF/anti-IL-1beta antibodies and methods of using the same.
    Type: Application
    Filed: December 20, 2019
    Publication date: June 25, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: ROLAND BECKMANN, JOERG BENZ, STEFAN DENGL, CHRISTIAN GASSNER, GUIDO HARTMANN, PETER MICHAEL HUELSMANN, SABINE IMHOF-JUNG, KRISTIAN HOBOLT JENSEN, HUBERT KETTENBERGER, STEFAN LORENZ, JOERG MOELLEKEN, OLAF MUNDIGL
  • Anti-IL-1beta antibodies
    Patent number: 10344085
    Abstract: Herein are reported humanized anti-IL-1beta antibodies that are humanized variants of the murine anti-IL-1beta antibody H34. A specific humanized antibody comprises (a) a HVR-H1 comprising the amino acid sequence of SEQ ID NO: 25, (b) a HVR-H2 comprising the amino acid sequence of SEQ ID NO: 27, and (c) a HVR-H3 comprising the amino acid sequence of SEQ ID NO: 28.
    Type: Grant
    Filed: May 9, 2017
    Date of Patent: July 9, 2019
    Assignee: Hoffman-La Roche, Inc.
    Inventors: Stefan Dengl, Peter Michael Huelsmann, Christian Gassner, Sebastian Breuer, Olaf Mundigl, Guy Georges, Ralf Schumacher, Guido Hartmann, Sabine Gruener
  • Anti-PDGF-B antibodies and methods of use
    Patent number: 10087246
    Abstract: Herein are reported anti-PDGF-B antibodies and their use in ophthalmology.
    Type: Grant
    Filed: May 9, 2017
    Date of Patent: October 2, 2018
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Marc Bedoucha, Sebastian Breuer, Stefan Dengl, Christian Gassner, Guy Georges, Sabine Gruener, Guido Hartmann, Peter Michael Huelsmann, Joerg Moelleken, Olaf Mundigl, Joerg Thomas Regula, Barbara Weiser
  • ANTI-PDGF-B ANTIBODIES AND METHODS OF USE
    Publication number: 20170247440
    Abstract: Herein are reported anti-PDGF-B antibodies and their use in ophthalmology.
    Type: Application
    Filed: May 9, 2017
    Publication date: August 31, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Marc Bedoucha, Sebastian Breuer, Stefan Dengl, Christian Gassner, Guy Georges, Sabine Gruener, Guido Hartmann, Peter Michael Huelsmann, Joerg Moelleken, Olaf Mundigl, Joerg Thomas Regula, Barbara Weiser
  • ANTI-IL-1beta ANTIBODIES AND METHODS OF USE
    Publication number: 20170247447
    Abstract: Herein are reported humanized anti-IL-1beta antibodies that are humanized variants of the murine anti-IL-1beta antibody H34. A specific humanized antibody comprises (a) a HVR-H1 comprising the amino acid sequence of SEQ ID NO: 25, (b) a HVR-H2 comprising the amino acid sequence of SEQ ID NO: 27, and (c) a HVR-H3 comprising the amino acid sequence of SEQ ID NO: 28.
    Type: Application
    Filed: May 9, 2017
    Publication date: August 31, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Stefan Dengl, Peter Michael Huelsmann, Christian Gassner, Sebastian Breuer, Olaf Mundigl, Guy Georges, Ralf Schumacher, Guido Hartmann, Sabine Gruener
  • BISPECIFIC ANTIBODIES AND METHODS OF USE IN OPHTHALMOLOGY
    Publication number: 20170240629
    Abstract: Herein are reported novel bispecific antibodies that specifically bind to two different antigens selected from the group consisting of human ANG2, human VEGF, human IL-1beta and human PDGF-B.
    Type: Application
    Filed: May 9, 2017
    Publication date: August 24, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Marc Bedoucha, Sebastian Breuer, Stefan Dengl, Christian Gassner, Guy Georges, Sabine Gruener, Guido Hartmann, Peter Michael Huelsmann, Hubert Kettenberger, Joerg Moelleken, Michael Molhoj, Olaf Mundigl, Joerg Thomas Regula, Ralf Schumacher, Barbara Weiser
  • USE OF N-(4-TERT-BUTYLBENZYL)-3-CHLORO-N-[2-(4-CHLORO-3-ETHYL-PHENYL)-ETHYL]-2-FLUORO-5-TRIFLUOROMETHYL-BENZAMIDE FOR THE TREATMENT OF EYE DISEASES
    Publication number: 20170035708
    Abstract: The present invention relates N-(4-tert-Butyl-benzyl)-3-chloro-N-[2-(4-chloro-3-ethyl-phenyl)-ethyl]-2-fluoro-5-trifluoromethyl-benz-amide which is useful in the prevention, treatment, delaying progression and/or reduction of eye diseases, in particular wherein the eye diseases are intraocular neovascular diseases and its method of preventing, retarding and ameliorating eye diseases, in particular intraocular neovascular diseases.
    Type: Application
    Filed: April 6, 2016
    Publication date: February 9, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Evelyne Chesne, Guido Hartmann
  • HUMAN FCRN-BINDING MODIFIED ANTIBODIES AND METHODS OF USE
    Publication number: 20160159894
    Abstract: Herein is reported the use of an antibody comprising an Fc-region with abolished FcRn binding for the transport of a soluble receptor ligand from the eye over the blood-ocular-barrier into the blood circulation.
    Type: Application
    Filed: October 29, 2015
    Publication date: June 9, 2016
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Guido Hartmann, Joerg Thomas Regula, Matthias Rueth, Wolfgang Schaefer, Tilman Schlothauer
  • FCRN-BINDING ABOLISHED ANTI-IGF-1R ANTIBODIES AND THEIR USE IN THE TREATMENT OF VASCULAR EYE DISEASES
    Publication number: 20160151487
    Abstract: The invention provides anti-IGF-1R antibodies with abolished FcRn-binding and methods of using the same for the treatment of vascular eye diseases.
    Type: Application
    Filed: October 29, 2015
    Publication date: June 2, 2016
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Guido Hartmann, Joerg Thomas Regula, Matthias Rueth, Wolfgang Schaefer, Tilman Schlothauer
  • Cyclic amides
    Patent number: 9290467
    Abstract: The invention relates to a compound of formula (I) wherein A, B, D and R1 to R6 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Grant
    Filed: January 10, 2013
    Date of Patent: March 22, 2016
    Assignee: HOFFMANN—LA ROCHE INC.
    Inventors: Lilli Anselm, David Banner, Jean-Baptiste Blanc, Delphine Gaufreteau, Wolfgang Haap, Guido Hartmann, Bernd Kuhn, Thomas Luebbers, Jens-Uwe Peters, Beat Spinnler